Regentatlantic Capital LLC cut its stake in Cigna Corporation (NYSE:CI) by 2.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,548 shares of the health services provider’s stock after selling 357 shares during the period. Regentatlantic Capital LLC’s holdings in Cigna Corporation were worth $2,603,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. E&G Advisors LP purchased a new position in Cigna Corporation during the second quarter valued at about $218,000. Breton Hill Capital Ltd. raised its position in Cigna Corporation by 91.2% in the second quarter. Breton Hill Capital Ltd. now owns 7,793 shares of the health services provider’s stock valued at $1,304,000 after buying an additional 3,717 shares in the last quarter. PGGM Investments purchased a new position in Cigna Corporation during the second quarter valued at about $21,588,000. Meag Munich Ergo Kapitalanlagegesellschaft MBH bought a new stake in shares of Cigna Corporation during the second quarter worth $4,205,000. Finally, Quantitative Systematic Strategies LLC raised its stake in shares of Cigna Corporation by 267.4% in the second quarter. Quantitative Systematic Strategies LLC now owns 13,955 shares of the health services provider’s stock worth $2,326,000 after buying an additional 10,157 shares during the period. 86.91% of the stock is currently owned by institutional investors and hedge funds.

Cigna Corporation (CI) opened at 172.55 on Monday. The company’s 50 day moving average is $170.76 and its 200 day moving average is $157.68. Cigna Corporation has a 52-week low of $115.03 and a 52-week high of $178.50. The firm has a market cap of $44.18 billion, a P/E ratio of 23.04 and a beta of 0.46.

Cigna Corporation (NYSE:CI) last announced its quarterly earnings data on Friday, August 4th. The health services provider reported $2.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.48 by $0.43. Cigna Corporation had a net margin of 7.46% and a return on equity of 17.58%. The firm had revenue of $10.32 billion during the quarter, compared to analysts’ expectations of $10.26 billion. During the same quarter last year, the business earned $1.98 earnings per share. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. Equities research analysts forecast that Cigna Corporation will post $9.79 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Regentatlantic Capital LLC Has $2.60 Million Position in Cigna Corporation (CI)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/07/regentatlantic-capital-llc-lowers-stake-in-cigna-corporation-ci-updated.html.

CI has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $178.00 price objective (up from $172.00) on shares of Cigna Corporation in a report on Sunday, April 23rd. Zacks Investment Research raised shares of Cigna Corporation from a “hold” rating to a “buy” rating and set a $175.00 price objective on the stock in a report on Tuesday, April 25th. Stifel Nicolaus boosted their price objective on shares of Cigna Corporation from $170.00 to $175.00 and gave the company a “buy” rating in a report on Friday, May 5th. Deutsche Bank AG boosted their price objective on shares of Cigna Corporation from $172.00 to $175.00 and gave the company a “buy” rating in a report on Wednesday, May 10th. Finally, Royal Bank Of Canada boosted their price objective on shares of Cigna Corporation from $172.00 to $177.00 and gave the company an “outperform” rating in a report on Monday, May 15th. Two analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Cigna Corporation has a consensus rating of “Buy” and an average price target of $177.17.

In related news, VP Mary T. Hoeltzel sold 500 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $166.70, for a total value of $83,350.00. Following the completion of the sale, the vice president now owns 2,449 shares in the company, valued at $408,248.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nicole S. Jones sold 20,312 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $160.04, for a total transaction of $3,250,732.48. Following the completion of the sale, the executive vice president now owns 44,737 shares of the company’s stock, valued at approximately $7,159,709.48. The disclosure for this sale can be found here. Insiders sold 219,558 shares of company stock valued at $37,135,665 in the last quarter. Company insiders own 1.30% of the company’s stock.

About Cigna Corporation

Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.

Institutional Ownership by Quarter for Cigna Corporation (NYSE:CI)

Receive News & Stock Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related stocks with our FREE daily email newsletter.